CTAG1A: A Potential Drug Target and Biomarker (G246100)

Target Name: CTAG1A

NCBI ID: G246100

CTAG1A

CTAG1A: A Potential Drug Target and Biomarker

CTAG1A, also known as CD28, is a cell adhesion molecule that is expressed in various tissues and cell types, including the brain, heart, and gastrointestinal tract. It plays a crucial role in cell-cell adhesion and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, CTAG1A has emerged as a promising drug target and biomarker for a variety of diseases.

The CTAG1A gene is located on chromosome 6p21 and encodes a 21-kDa protein that is expressed in various tissues and cell types. It is highly conserved across species and has been shown to be involved in a number of cellular processes, including cell adhesion, migration , and survival.

One of the most significant functions of CTAG1A is its role in cell adhesion. CTAG1A is a member of the cadherin family of transmembrane proteins, which are involved in the formation of tight junctions and adherens junctions, which are critical for maintaining tissue structure and function. In addition, CTAG1A is involved in the regulation of cell adhesion, as it has been shown to play a role in the formation of tight junctions in epithelial cells.

The other important function is cell survival. Loss of CTAG1A has been shown to lead to increased incidence of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. In addition, CTAG1A is also related to cell survival because it is one of the key genes for cell survival.

Recently, studies have shown that CTAG1A may be a potential drug target. Researchers found that CTAG1A is up-regulated in a variety of cancers and has good tumorigenesis potential. In addition, there is evidence that CTAG1A is related to tumor development and progression and therefore can be used as a potential therapeutic target for tumors.

In addition, studies have shown that CTAG1A is also related to neurodegenerative diseases. For example, studies have shown that loss of CTAG1A is associated with the onset of Alzheimer's disease and Parkinson's disease. In addition, researchers also found that CTAG1A is associated with neurodegenerative diseases and autism, which provides new ideas for developing drugs to treat these diseases.

Overall, CTAG1A is a potential drug target that can be used to treat a variety of diseases. Although current research shows that CTAG1A has great potential in treating cancer and neurodegenerative diseases, further research is needed to determine its effectiveness and safety as a drug target.

Protein Name: Cancer/testis Antigen 1A

The "CTAG1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTAG1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets